Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors

Special Survey of Production of Antibody Against Coagulation

This study is conducted in Japan. The aim of this registry study is to observe the use of single dose and multi-dose use of eptacog alpha (NovoSeven®) and to compare short-term outcomes, including effectiveness, safety, quality of life and treatment satisfaction with the approved treatments.

Inclusion Criteria:

• Treated with eptacog alpha (NovoSeven®)

Exclusion Criteria:

• Investigator decision to measure for antibody as unnecessary medical testing